Mild To Moderate Plaque Psoriasis Market: Epidemiology, Therapies, Companies Working, DelveInsight | AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lil

Most Psoriasis Patients (78%) have mild or moderate illness ( 10% body surface area involved), with mild disease accounting for 50% of cases ( 3% body surface area involved). Only 2% of individuals have a body surface area involvement greater than 50%.

Emerging therapies like INBRX-109, TIBSOVO (ivosidenib), and others are anticipated to drive growth in the Mild to Moderate Plaque Psoriasis market in the coming years.

DelveInsight has launched a new report on "Mild To Moderate Plaque Psoriasis - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the Mild To Moderate Plaque Psoriasis, historical and forecasted epidemiology as well as the Mild To Moderate Plaque Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our sample report @ https://www.delveinsight.com/report-store/mild-to-moderate-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Mild To Moderate Plaque Psoriasis Market Report:

*
The Mild-to-Moderate Plaque Psoriasis market is expected to witness notable growth at a significant CAGR during the forecast period (2023-2032).

*
In 2024, China approved Jinlixi, a monoclonal antibody targeting interleukin-17A, for adults with moderate-to-severe plaque psoriasis. Similarly, the FDA approved Sotyktu in September 2022, an oral TYK2 inhibitor offering a new treatment approach for this patient group.

*
Additionally, the FDA greenlit biosimilars such as ustekinumab-kfce (Yesintek) and ustekinumab-stba (Steqeyma) in December 2024, expanding treatment choices. Johnson & Johnson's oral drug icotrokinra also showed promise by achieving primary endpoints in a late-stage trial, with 64.7% of patients experiencing significant skin clearance at 16 weeks.

*
Otezla's indication was expanded by the FDA in December 2021 to include plaque psoriasis across all severities-making it the first and only oral therapy approved for mild, moderate, and severe forms of the condition.

*
Leading pharmaceutical companies-including AbbVie, Pfizer, Johnson & Johnson, Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, and Arcutis Biotherapeutics-are actively engaged in advancing treatments for mild-to-moderate plaque psoriasis.

*
Around 78% of psoriasis patients have mild to moderate disease (affecting less than or equal to 10% of body surface area), with mild cases alone accounting for 50% of the total. Severe cases involving more than 50% of the body are seen in only about 2% of patients.

*
A 2021 online U.S.-based survey by Gupta et al. involving 175 patients with mild-to-moderate plaque psoriasis revealed that 67.4% were female, with a median age of 55 years and an average disease duration of 10.8 years.

*
Notable pipeline therapies for this segment include Otezla, SGX302, AKP02/AKVANO, and others, showing strong promise in clinical development.

Key benefits of the Mild To Moderate Plaque Psoriasis market report:

*
Mild To Moderate Plaque Psoriasis market report covers a descriptive overview and comprehensive insight of the Mild To Moderate Plaque Psoriasis Epidemiology and Mild To Moderate Plaque Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

*
The Mild To Moderate Plaque Psoriasis market report provides insights on the current and emerging therapies.

*
Mild To Moderate Plaque Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Mild To Moderate Plaque Psoriasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Mild To Moderate Plaque Psoriasis market.

Got queries? Click here to know more about the Mild To Moderate Plaque Psoriasis Market Landscape [https://www.delveinsight.com/sample-request/mild-to-moderate-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Mild To Moderate Plaque Psoriasis Overview

Psoriasis is a chronic, immune-driven skin condition that speeds up the skin cell regeneration process, causing cells to build up about 10 times faster than normal. This rapid growth results in thick, red patches covered with silvery scales, often accompanied by intense itching. These patches are most commonly found on the elbows, knees, scalp, lower back, face, palms, and soles, but can also affect areas like the nails and mouth.

Plaque psoriasis is the most common type, representing around 80% of all cases. Diagnosis is typically based on a physical examination of the skin, scalp, and nails for classic signs. In certain cases, a skin biopsy may be required, where a dermatopathologist examines a tissue sample, usually obtained through a punch biopsy, to confirm the diagnosis.

To know more about the Mild To Moderate Plaque Psoriasis treatment algorithms [https://www.delveinsight.com/report-store/mild-to-moderate-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Mild To Moderate Plaque Psoriasis Treatment Market

According to the American Academy of Dermatology (AAD) treatment guidelines, management of localized mild-to-moderate plaque psoriasis should begin with educating the patient and using topical corticosteroids, either alone or combined with agents like coal tar or calcipotriene.

If this initial approach is ineffective or loses efficacy over time, second-line treatments such as anthralin or tazarotene-used alone or alongside corticosteroids-may be considered.

For patients with difficult-to-control symptoms or more extensive disease, phototherapy may be required, either on its own or in combination with medications such as psoralen or retinoids.

Mild To Moderate Plaque Psoriasis Market Outlook

Topical treatments are the primary approach for managing localized plaque psoriasis, while light therapy is also commonly used for mild-to-moderate cases. Frequently used phototherapy methods include full-body or targeted UVB (both broad and narrowband), PUVA (photochemotherapy), home-based phototherapy, and LASER treatments.

Systemic therapies encompass a range of drugs such as acitretin, methotrexate, cyclosporine, tacrolimus, hydroxyurea, 6-thioguanine, mycophenolate, fumaric acid esters, apremilast, and biologic agents. Approved biologics for plaque psoriasis include etanercept, adalimumab, infliximab, secukinumab, ustekinumab, tildrakizumab, and ixekizumab.

DelveInsight projects that the Mild-to-Moderate Plaque Psoriasis Market across the 7MM (U.S., EU5, and Japan) will experience notable developments throughout the 2019-2032 forecast period.

Know more about the rising Mild To Moderate Plaque Psoriasis market [https://www.delveinsight.com/sample-request/mild-to-moderate-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Mild To Moderate Plaque Psoriasis Emerging Drugs

*
SGX302: Soligenix

*
AKP02/AKVANO: Lipidor AB

Mild To Moderate Plaque Psoriasis Marketed Drugs

*
Otezla: Amgen

Scope of the Mild To Moderate Plaque Psoriasis Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Mild To Moderate Plaque Psoriasis Companies: AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, and others

*
Key Mild To Moderate Plaque Psoriasis Therapies: Otezla, SGX302, AKP02/AKVANO, and others

*
Mild To Moderate Plaque Psoriasis Therapeutic Assessment: Mild To Moderate Plaque Psoriasis current marketed and Mild To Moderate Plaque Psoriasis emerging therapies

*
Mild To Moderate Plaque Psoriasis Market Dynamics: Mild To Moderate Plaque Psoriasis market drivers and Mild To Moderate Plaque Psoriasis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Mild To Moderate Plaque Psoriasis Unmet Needs, KOL's views, Analyst's views, Mild To Moderate Plaque Psoriasis Market Access and Reimbursement

To get detailed insights on the scope of our Mild To Moderate Plaque Psoriasis market report [https://www.delveinsight.com/report-store/mild-to-moderate-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Mild To Moderate Plaque Psoriasis Patient Share (%) Overview at a Glance

5. Mild To Moderate Plaque Psoriasis Market Overview at a Glance

6. Mild To Moderate Plaque Psoriasis Disease Background and Overview

7. Mild To Moderate Plaque Psoriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Mild To Moderate Plaque Psoriasis

9. Mild To Moderate Plaque Psoriasis Current Treatment and Medical Practices

10. Unmet Needs

11. Mild To Moderate Plaque Psoriasis Emerging Therapies

12. Mild To Moderate Plaque Psoriasis Market Outlook

13. Country-Wise Mild To Moderate Plaque Psoriasis Market Analysis (2019-2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Mild To Moderate Plaque Psoriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Mild To Moderate Plaque Psoriasis Pipeline Insights, DelveInsight

"Mild To Moderate Plaque Psoriasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Mild To Moderate Plaque Psoriasis market. A detailed picture of the Mild To Moderate Plaque Psoriasis pipeline landscape is provided, which includes the disease overview and Mild To Moderate Plaque Psoriasis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mild-to-moderate-plaque-psoriasis-market-epidemiology-therapies-companies-working-delveinsight-abbvie-pfizer-johnson-johnson-jj-bristolmyers-squibb-ucb-pharma-amgen-novartis-eli-lil]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.